ANI Pharmaceuticals Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
May 7, 2021 6:52 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.33 better than the analyst estimate of $0.71. Revenue for the quarter came in at $54.5 million versus the consensus estimate of $46.8 million.
First Quarter 2021 Financial Highlights:
Net revenues were $54.5 million compared to $49.8 million in Q1 2020.GAAP net income was $0.1 million, and diluted GAAP earnings per share was $0.01.Adjusted non-GAAP EBITDA was $18.9 million.Adjusted non-GAAP diluted earnings per share was $1.04.Cash and cash equivalents were $25.1 million, net accounts receivable was $91.9 million,... More
